These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


231 related items for PubMed ID: 27567833

  • 1. Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma.
    Pérez-Grijalba V, Fandos N, Canudas J, Insua D, Casabona D, Lacosta AM, Montañés M, Pesini P, Sarasa M.
    J Alzheimers Dis; 2016 Sep 06; 54(2):751-62. PubMed ID: 27567833
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Plasma Amyloid Concentration in Alzheimer's Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer's Disease Cases from Controls.
    Feinkohl I, Schipke CG, Kruppa J, Menne F, Winterer G, Pischon T, Peters O.
    J Alzheimers Dis; 2020 Sep 06; 74(4):1285-1294. PubMed ID: 32176645
    [Abstract] [Full Text] [Related]

  • 4. Multiplex immunoassay measurement of amyloid-β42 to amyloid-β40 ratio in plasma discriminates between dementia due to Alzheimer's disease and dementia not due to Alzheimer's disease.
    Vogelgsang J, Shahpasand-Kroner H, Vogelgsang R, Streit F, Vukovich R, Wiltfang J.
    Exp Brain Res; 2018 May 06; 236(5):1241-1250. PubMed ID: 29480353
    [Abstract] [Full Text] [Related]

  • 5. Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease.
    Kim HJ, Park KW, Kim TE, Im JY, Shin HS, Kim S, Lee DH, Ye BS, Kim JH, Kim EJ, Park KH, Han HJ, Jeong JH, Choi SH, Park SA.
    J Alzheimers Dis; 2015 May 06; 48(4):1043-50. PubMed ID: 26444752
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid-β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort.
    Klafki HW, Hafermann H, Bauer C, Haussmann U, Kraus I, Schuchhardt J, Muck S, Scherbaum N, Wiltfang J.
    J Alzheimers Dis; 2016 Sep 06; 54(2):691-705. PubMed ID: 27567847
    [Abstract] [Full Text] [Related]

  • 11. Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab.
    Lachno DR, Evert BA, Vanderstichele H, Robertson M, Demattos RB, Konrad RJ, Talbot JA, Racke MM, Dean RA.
    J Alzheimers Dis; 2013 Sep 06; 34(4):897-910. PubMed ID: 23302661
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls.
    Pannee J, Portelius E, Oppermann M, Atkins A, Hornshaw M, Zegers I, Höjrup P, Minthon L, Hansson O, Zetterberg H, Blennow K, Gobom J.
    J Alzheimers Dis; 2013 Sep 06; 33(4):1021-32. PubMed ID: 23076076
    [Abstract] [Full Text] [Related]

  • 14. An optimized UPLC-MS/MS method for human plasma amyloid-β 42 and 40 measurement and application in Alzheimer's disease diagnosis.
    Zhang Q, Bai K, Jin X, Zhan M, Han L, Zhuang J, Huang X.
    J Pharm Biomed Anal; 2024 Nov 15; 250():116396. PubMed ID: 39128283
    [Abstract] [Full Text] [Related]

  • 15. Quantification of Amyloid-β in Plasma by Simple and Highly Sensitive Immunoaffinity Enrichment and LC-MS/MS Assay.
    Iino T, Watanabe S, Yamashita K, Tamada E, Hasegawa T, Irino Y, Iwanaga S, Harada A, Noda K, Suto K, Yoshida T.
    J Appl Lab Med; 2021 Jul 07; 6(4):834-845. PubMed ID: 33462584
    [Abstract] [Full Text] [Related]

  • 16. Validation of a Chemiluminescence Immunoassay for Measuring Amyloid-β in Human Blood Plasma.
    Vogelgsang J, Wiltfang J, Klafki HW.
    Methods Mol Biol; 2018 Jul 07; 1750():111-124. PubMed ID: 29512068
    [Abstract] [Full Text] [Related]

  • 17. Label-free detection of β-amyloid peptides (Aβ40 and Aβ42): a colorimetric sensor array for plasma monitoring of Alzheimer's disease.
    Ghasemi F, Hormozi-Nezhad MR, Mahmoudi M.
    Nanoscale; 2018 Apr 05; 10(14):6361-6368. PubMed ID: 29561053
    [Abstract] [Full Text] [Related]

  • 18. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M, DidierLaurent G, Latarche C, Escanyé MC, Olivier JL, Malaplate-Armand C.
    J Alzheimers Dis; 2014 Apr 05; 41(2):377-86. PubMed ID: 24614902
    [Abstract] [Full Text] [Related]

  • 19. Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics.
    Lachno DR, Emerson JK, Vanderstichele H, Gonzales C, Martényi F, Konrad RJ, Talbot JA, Lowe SL, Oefinger PE, Dean RA.
    J Alzheimers Dis; 2012 Apr 05; 32(4):905-18. PubMed ID: 22886018
    [Abstract] [Full Text] [Related]

  • 20. A Sensitive and Cost-Effective Chemiluminescence ELISA for Measurement of Amyloid-β 1-42 Peptide in Human Plasma.
    Mehta PD, Patrick BA, Miller DL, Coyle PK, Wisniewski T.
    J Alzheimers Dis; 2020 Apr 05; 78(3):1237-1244. PubMed ID: 33252086
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 12.